New Treatment Schedule for Pancreatic Cancer
Author Information
Author(s): Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G, Francini G
Primary Institution: Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine
Hypothesis
The combination of GEM plus FUFA is active in the treatment of pancreatic carcinoma.
Conclusion
The novel biweekly treatment schedule combining GEM, 5-FU, and FA showed promising antitumor activity and improved patient survival.
Supporting Evidence
- The treatment was well tolerated with no grade IV toxicity recorded.
- An objective response was recorded in 13 out of 42 patients.
- The overall survival was 13.1 months with some patients alive after 42 months.
Takeaway
Doctors tested a new way to give medicine to help people with pancreatic cancer, and it seemed to work better than before.
Methodology
Patients received a combination of FA, 5-FU, and GEM in a biweekly schedule, with assessments of response and toxicity.
Limitations
The study was limited by its small sample size and the lack of a control group.
Participant Demographics
42 patients (28 males and 14 females) with an average age of 61 years.
Statistical Information
Confidence Interval
95% CI 6.88–12.62 for time to progression; 95% CI 9.64–16.56 for overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website